Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Presented interim FRONTIER4 data evaluate the long-term safety and efficacy of investigational denecimig across once-weekly, once-every-two-weeks, and once-monthly dosing in hemophilia A participants of all ages and disease severities1,2Denecimig is an investigational subcutaneous FVIIIa-mimetic antibody under review with…

Read the full release →

News provided by PR Newswire.